Current Report Filing (8-k)
27 Fevereiro 2019 - 6:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 21, 2019
AVID BIOSERVICES,
INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-32839
|
|
95-3698422
|
(State of other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
2642 Michelle Drive, Suite 200, Tustin, California 92780
|
(Address of Principal Executive Offices)
|
|
|
|
|
|
Registrant’s telephone number, including area code:
(714) 508-6100
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On February 21, 2019,
the Compensation Committee of the Board of Directors of Avid Bioservices, Inc. (the “Company”), approved a modification
to the relocation benefits payable to Roger J. Lias, Ph.D., the Company’s President and Chief Executive Officer, under the
terms of his employment.
As previously reported,
the Company agreed to provide Dr. Lias with a monthly housing stipend of up to $3,200 per month for a period of up to thirty-six
(36) months, or his earlier permanent relocation to Orange County, California. The foregoing amounts will be grossed up to offset
federal and California income taxes. In the event that Dr. Lias relocates to Orange County, California within the foregoing thirty-six
(36) month period, the Company will pay to Dr. Lias a relocation bonus of $50,000 to cover the costs associated with the relocation.
The relocation bonus will not be grossed up for federal or California income tax purposes.
As modified by the
Compensation Committee on February 21, 2019, in the event that Dr. Lias permanently relocates to Orange County, California by October
1, 2019, the Company will pay to Dr. Lias a relocation bonus in the amount of $50,000, which will not be grossed up for federal
and California income taxes. In the event that Dr. Lias relocates after October 1, 2019, but prior to the expiration of the above
thirty-six (36) month period, the amount of such bonus will be reduced proportionately to zero if Dr. Lias does not relocate by
the expiration of the thirty-six (36) month period. The relocation bonus will not be grossed up to offset federal and California
income taxes. As further modified by the Compensation Committee on February 21, 2019, in the event that Dr. Lias relocates to Orange
County, California within the thirty-six (36) month period, the Company will reimburse Dr. Lias for his relocation expenses incurred
in an amount not to exceed $50,000, in lieu of paying such amount to him as a bonus as originally structured. With respect to the
relocation bonus and the reimbursement of relocation expenses, in the event that Dr. Lias terminates his employment (i) within
six months following such relocation, he will continue to be required to return to the Company one hundred percent (100%) of the
relocation bonus, or (ii) during months seven (7) through twenty-four (24) following such relocation, he will be required to return
a pro-rata portion of the relocation bonus.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AVID BIOSERVICES, INC.
|
|
|
|
|
Date: February 27, 2019
|
By:
/s/ Daniel R. Hart
|
|
Daniel R. Hart
|
Avid Bioservices (NASDAQ:CDMOP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Avid Bioservices (NASDAQ:CDMOP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024